Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | CASP1 | P29466 | 4/20 | 0.31 |
| ▸ | CASP7 | P55210 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179435 | 0.80 | CYP11B1 (0.40) | NQO1CYP11B1CYP11B2RXFP1ALDH1A1 | |
| SCHEMBL2176126 | 0.77 | ADORA2A (0.30) | ADORA1 | |
| SCHEMBL1515421 | 0.74 | — | — | |
| SCHEMBL2177830 | 0.71 | ALDH1A1 (0.38) | CYP11B1CYP11B2ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL2180063 | 0.71 | — | — | |
| SCHEMBL896600 | 0.71 | — | — | |
| SCHEMBL895932 | 0.69 | — | — | |
| SCHEMBL1022718 | 0.69 | — | — | |
| SCHEMBL2176290 | 0.69 | — | — | |
| SCHEMBL2181274 | 0.69 | CYP11B1 (0.36) | CYP11B1CYP11B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598176-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| US-20110166162-A1 | 1,2-Benzisothiazole Compounds Useful for Combating Animal Pests | BASF SE (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-1958946-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1958946-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166162-A1 | 1,2-Benzisothiazole Compounds Useful for Combating Animal Pests | GLRX3, CBR3, PRDX1 | NQO1 1276/4885HPGDS 4112/4885CYP11B1 3619/4885 |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | NQO1 367/4885HPGDS 2246/4885CYP11B1 355/4885 |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, PDXK | NQO1 367/4885HPGDS 2246/4885CYP11B1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.